Presentations 2012
SHM’s staff give presentations on several occasions throughout the year with findings from research and papers presented at conferences worldwide. Below you can find an overview of the presentations in 2012.
- Update on the HIV epidemic in the Netherlands
Frank de Wolf
Presentation - Pre-exposure prophylaxis amongst men who have sex with men in the netherlands
Ard van Sighem
Presentation - Changes in first-line cART regimens and clinical outcome between 1996 and 2010 in the Netherlands
Smit M, Smit C, Geerlings S, Gras L, Garnett G, Hallett T, de Wolf F. - HIV-1 transmission networks on Curaçao, a Caribbean Island
Daniela Bezemer
Poster - CD4 cell count changes following acute HCV infection in chronically HIV infected patients
Luuk Gras
Poster - Long-term CD4 cell count improvement in HIV-1 infected individuals with long-term sustained viral suppression on combination antiretroviral therapy
Luuk Gras
Poster - Response to anti-HCV treatment in HIV-infected patients chronically infected with Hepatitis C, the NVHB-SHM Hepatitis working group
Colette Smit
Poster - Decreased incidence of Pneumocystis jirovecii pneumonia among sub-Saharan African patients in the Dutch ATHENA cohort; genetic susceptibility or environmental factors?
Schoffelen A, van Lelyveld S, Barth R, Gras L, de Wolf F, Netea M, Hoepelman A. - An overview of the Dutch pediatric vertically HIV-infected population in the era of cART
Cohen S, Smit C, Pajkrt D, for the Dutch Pediatric HIV Study Group (PHON).
11th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, 11-15 November 2012
- When to switch cART: Novel methods for the comparison of switching strategies using observational data
Cain LE, Sterne JAC, May MT, Ingle SM, Abgrall S, Saag MS and Hernán MA on behalf of the HIV-CAUSAL Collaboration and the ART-CC. - Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA
Grint D, Mocroft A, Vogel M, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O an Peters L for EuroSIDA in EuroCOORD. - Computational models that predict response to HIV therapy may reduce virological failure and therapy costs in resource-limited settings
Revell AD, Wang D, Alvarez-Uria G, Streinu-Cercel A, Ene L, Wensing AMJ, Hamers RL, Morrow C, Robin WOOD, Tempelman H, De Wolf F, Nelson M, Montaner JS, Lane HC12, Larder BA on behalf of the RDI study group. - CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use
Mocroft A, Phillips A, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Kirk O, Lundgren J et al for the EuroSIDA study in EuroCoord. - Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected?
Rockstroh JK, Grint D, Boesecke C, Soriano V, Lundgren JD, d’Arminio Monforte A, Mitsura VM, Kirk O, Mocroft A and Peters L for EuroSIDA in EuroCoord. - Immuno-virological discordance (ID) is associated with a higher frequency of fatal and non-fatal AIDS and non-AIDS
Zoufaly A, Cozzi-Lepri A, Kirk O, Lundgren JD, Reiss P, Jetovic D, Machala L, Zangerle R, Mocroft A, van Lunzen J on behalf of EuroSIDA in EuroCoord. - Advanced chronic kidney disease, endstage renal disease and renal death in HIV-positive individuals in Europe
Ryom L, Kirk O, Lundgren JD, Pedersen C, Reiss P, De Wit S, Buzunova S, Gasiorowski J, Gatell JM and Mocroft A on behalf of EuroSIDA in EuroCoord. - Impact of antiretroviral therapy (ART), viraemia and immunosuppression on lipid levels: the D:A:D Study
Kamara DA, Sabin C, Reiss P, Rickenbach M, Smith C, De Wit S, Law M, Mocroft A, Pradier C, Lundgren JD.
- General overview of main approaches for estimating people living with HIV
Van Sighem A. - Use of longitudinal case reporting data for estimation HIV prevalence
Van Sighem A.
- SHM: Monitoring of HIV in the Netherlands
De Wolf F, Van Sighem A.
http://eeas.europa.eu/delegations/kazakhstan/press_corner/all_news/news/2012/20120516_1_en.htm
- Comorbidity and ageing in HIV-1 infection: the AGEhIV Cohort Study
Schouten J, Wit FW, Stolte IG, van der Valk M, Geerlings SE, de Wolf F, Prins M, Reiss P, on behalf of the AGEhIV Cohort Study Group. - Characteristics of individuals presenting late for care across Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
Jens D Lundgren on behalf of the late presenters working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. - Non-AIDS defining malignancies (NADM) and immunosuppression: The D:A:D study
Worm SW, Bower M, Reiss P, Grulich A, Fontas E, Bonnet F, Faetkenheuer G, Law M, Phillips A, Furrer HJ, El-Sadr W, Kirk O, Ryom L, Abrams D, D’Arminio Monforte A, De Wit S, Sabin C, Lundgren JD on behalf of the D:A:D study group. - Trends over time in underlying causes of death in the D:A:D Study from 1999 to 2011
Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska J, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD for the D:A:D Study Group.
- HBV and HCV in HIV-infected patients in care
Smit C. - Effectiviteit HIV-testbeleid
Van Sighem A.
- Does (early) cART have a public health benefit?
Frank de Wolf
Presentation
- Limited contribution to new infections from HIV-infected men who have sex with men on suppressive antiretroviral therapy
Ard van Sighem
Presentation
- HIV Treatment and Resistance in Curaçao
Frank de Wolf
Presentation
- Higher rates of AIDS and death during the first year of therapy among those born outside Europe, the United States, and Canada: the importance of tuberculosis
Shepherd BE, Jenkins CA and Sterling on behalf of ART-CC. - Effect of hepatitis C treatment on the risk of death in HIV/HCV co-infected patients; European Cohort Collaboration (COHERE) in EuroCoord.
Colette Smit (presenter), on behalf of the HCV working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord - Mortality after starting antiretroviral therapy (ART) in treatment-naïve adults in three continents: collaborative analysis of IeDEA and ART-CC cohorts
Boulle A, Schomaker M, Gsponder T, May M, Ingle S, Egger M and Sterne J for the IeDEA-SA and ART-CC cohort collaborations. - When to switch cART: Novel methods for the comparison of switching strategies using observational data
Cain LE, Sterne JAC, May MT, Ingle SM, Abgrall S, Saag MS and Hernán MA on behalf of the HIV-CAUSAL Collaboration and the ART-CC. - Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA
Grint D, Mocroft A, Vogel M, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O an Peters L for EuroSIDA in EuroCOORD. - Emulating randomized trials with dynamic strategies: an empirical comparison between effect estimates from randomized and observational studies
Young JG, Cain LE and Hernán MA on behalf of the HIV-CAUSAL Collaboration. - Comorbidity and Ageing in HIV-1 infection
Schouten J, Wit FM, Stolte IG, van der Valk M, Geerlings SE, de Wolf F, Prins M, Reiss P, on behalf of the AGEhIV Study Group. - Advanced Renal Disease and End-Stage Renal Disease in Europe
Ryom L, Kik O, Kundgren JD, Pedersen C, Reiss P, de Wit S, Kutsyna G, Gasiorowski J, Gatell J and Mocroft M on behalf of EuroSIDA in EuroCOORD. - CD4 cell count changes following acute HCV infection in chronically HIV infected patients.
Luuk Gras (presenter), Colette Smit, Maria Prins, Frank de Wolf, Janke Schinkel, Femke Lambers, Joost van Hommerig, Jan van der Meer, Ronald Geskus and the ATHENA national observational HIV cohort
Poster - Delayed entry into care after HIV diagnosis in Curacao.
Gonneke Hermanides (presenter), Ard van Sighem, Cai Winkel, Izzy Gerstenbluth, Frank de Wolf, Ashley Duits
Poster - Temporal trends in late presenters across the European continent
Reekie J, Mocroft A, Raben D, Lundgren J, and Kirk O on behalf of COHERE in EuroCoord. - Underreporting of TB-HIV co-infection in the national TB surveillance register in the Netherlands: a capture-recapture analysis
Van Leth F, Wit F, Kalisvaart N, Hillebregt M. Verbon A, Verhagen M, Sprenger H, Kiers A and Cobelens F. - History of injection drug use (IDU) and Hepatitis C as risk factors for mortality in the ART-CC
May M. Birnie K, Justice A, Hogg B, Ingle S, Sterne JAC on behalf of the Antiretroviral Therapy Cohort Collaboration (ART-CC). - Associations of risk group, gender and age with specific causes of death in the ART-CC
Ingle S, Gill J, Mugavero M, Lewden C, Abgrall S, Fätkenheuer G, Reiss P, May M, Sterne JAC and Saag M for the Antiretroviral Therapy Cohort Collaboration (ART-CC). - Fasting and non-fasting cholesterol and risk of myocardial infarction (MI): The D:A:D Study Group
Kamara DA, Worm SW, Sabin CA, Smith CJ, Philips A and Lundgren JD for the D:A:D Study Group. - Association of duration of HIV-infection, immunodeficiency and use of cART with the risk of severe chronic liver disease
Kesselring A, Wit F, Smit C, van der Valk M, Richter C, Reiss P and de Wolf F. - Low CD4 in recently-infected individuals and the proportion experiencing rapid progression
Olson A on behalf of the CASCADE Collaboration in EuroCOORD. - HIV-1 transmission networks in Curacao.
Daniela Bezemer (presenter)
- Estimating HIV prevalence in European countries
Ard van Sighem (presenter)
Presentation
- Non-AIDS defining malignancies (NADM) and immunosuppression: The D:A:D study
Worm SW, Bower M, Reiss P, Grulich A, Fontas E, Bonnet F, Faetkenheuer G, Law M, Phillips A, Furrer HJ, El-Sadr W, Kirk O, Ryom L, Abrams D, D'Arminio Monforte A, De Wit S, Sabin C, Lundgren JD on behalf of the D:A:D study group. - Evolution of HIV-1 Set-Point Viral Load within Transmission Networks
Daniela Bezemer (presenter), Luuk Gras, Ard van Sighem, Ben Berkhout, Christophe Fraser, Frank de Wolf
Poster - Risk of HIV viremia depends on length of prior suppression <50 copies/ml and is increased in sub Sahara African patients living in the Netherlands
Luuk Gras (presenter), Colette Smit, Marijn de Bruin, Daniela Bezemer, Jan Prins, Frank de Wolf, and the ATHENA national observational cohort
Poster - Distribution of age at death and degree of immunosuppression vary according to cause of death in people with HIV-1
Gill J, Ingle S, Mugavero M, Lewden C, Abgrall S, Fätkenheuer G, Reiss P, May M, Sterne J, and Saag M for the Antiretroviral Therapy Cohort Collaboration (ART-CC). - Cumulative incidence of and risk factors for changes to first ART regimen and death prior to a change: the Antiretroviral Therapy Cohort Collaboration (ART-CC)
Abgrall S, Ingle S, Saag M, Cavassini M, Hogg R, Crane H, May M, Sterne J, and the Antiretroviral Therapy Cohort Collaboration (ART-CC). - Proportion of HIV Elite Controllers and Loss of Elite Status According to 2 Commonly Used Definitions
Olson A, Meyer L, Prins M, Thiebaut R, Guiguet M, Chaix M-L, Amornkul P, Babiker A, Porter K, and CASCADE Collaboration in EuroCoord. - Identification of Severe Primary HIV Infection through Clinical, Immunological and Virological Definitions
Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Porter K, and CASCADE Collaboration in EuroCoord. - Exposure to Antiretrovirals (ARVs) and the Risk of Renal Impairment among HIV+ Persons with Normal Baseline Renal Function: the D:A:D Study
Ryom L, Mocroft A, Worm SW, Kamara DA, Reiss P, Ross M, Fux C, Morlat P, Moranne O, Smith C, Kirk O and Lundgren JD on behalf of the D:A:D study group. - Atazanavir (ATV)-Containing Antiretroviral Treatment is not Associated with an Increased Risk of Cardio- or Cerebro-Vascular Events (CVE) in the D:A:D Study
d’Arminio Monforte A, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, Worm SW, Phillips A, Lundgren J, and Sabin C. - Associations between Markers of Immunosuppression and the Risk of Cardiovascular Disease (CVD): the D:A:D Study
Sabin C, Worm SW, Law M, El-Sadr W, Reiss P, Bruyand M, Fontas E, d’Arminio Monforte A, Weber R, Kirk O, de Wit S, Lundgren JD on behalf of the D:A:D Study Group.
- HIV prevalence estimates
Van Sighem A.
http://ecdc.europa.eu/en/activities/surveillance/sti/pages/index.aspx
- Tenofovir/emtricitabine versus abacavir/lamivudine
Rebecca Holman (presenter), Luuk Gras, Jan Prins en Frank de Wolf
Presentation